Capricor Therapeutics (NASDAQ:CAPR) Trading Down 5.6% – Should You Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price dropped 5.6% on Monday . The company traded as low as $21.93 and last traded at $21.9050. 678,066 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 1,270,188 shares. The stock had previously closed at $23.21.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CAPR shares. Piper Sandler reiterated an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Roth Mkm restated a “buy” rating and set a $38.00 price target on shares of Capricor Therapeutics in a report on Friday, May 15th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a research report on Thursday, June 25th. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. Finally, B. Riley Financial boosted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.67.

Capricor Therapeutics Stock Down 5.4%

The firm has a market cap of $1.27 billion, a P/E ratio of -9.51 and a beta of 0.42. The stock’s 50-day moving average is $28.87 and its 200-day moving average is $28.28.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, analysts expect that Capricor Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Insider Activity at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction on Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 50,000 shares of company stock worth $1,551,658. 9.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently made changes to their positions in CAPR. KBC Group NV acquired a new stake in shares of Capricor Therapeutics during the first quarter worth approximately $44,000. ACT Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter worth approximately $43,000. GoalVest Advisory LLC bought a new stake in Capricor Therapeutics during the 4th quarter worth approximately $59,000. Allworth Financial LP grew its position in Capricor Therapeutics by 5,021.5% during the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 3,264 shares during the last quarter. Finally, State of Wyoming increased its holdings in Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.